2024/11/01

Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.

2024/10/10

Annual update has been made to our Sustainability site.

2024/05/08

Received ‘AA’ for the first time in MSCI ESG Ratings

2023/12/15

NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx ^TM IN JAPAN

2023/10/19

Updated information of sustainability